Pascal Sorio, CEO of AstraZeneca, a multinational pharmaceutical company headquartered in London, UK, said, "I think we have found a formula for success that can benefit from two doses of the vaccine." It.
The COVID-19 vaccine developed by AstraZeneca and Oxford University showed different immunity effects depending on the dose as a result of an interim analysis of the phase 3 clinical trial.
When two full-dose vaccines were administered, the prevention rate was only 62.1%, but the first half-dose and the second full-dose increased the prevention rate to 90.0%.
The average prevention rate is 70.4%, which is less effective than vaccines from Pfizer and German Bioentech (95%) and vaccines developed by US pharmaceutical company Modena (94.5%).
CEO Sorio said, "It can be 100% prevented" of COVID-19 infection, which is severe enough to require hospitalization. "We can't go into detail because we will release a vaccine at some point."
"AstraZeneca and Oxford are currently working on a new version of the vaccine," he said.
On the 21st, AstraZeneca and Oxford University applied for emergency use of the Corona 19 vaccine made by both companies to the UK Medicines and Health Care Product Regulatory Authority (MHRA).
(Photo = Getty Image Korea)